A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

Christina D. Drenberg; Anang Shelat; Jinjun Dang; Anitria Cotton; Shelley J. Orwick; Mengyu Li; Jae Yoon Jeon; Qiang Fu; Daelynn R. Buelow; Marissa Pioso; Shuiying Hu; Hiroto Inaba; Raul C. Ribeiro; Jeffrey E. Rubnitz; Tanja A. Gruber; R. Kiplin Guy; Sharyn D. Baker

doi:10.1038/s41467-019-09917-0

A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

Christina D. Drenberg, Anang Shelat, Jinjun Dang, Anitria Cotton, Shelley J. Orwick, Mengyu Li, Jae Yoon Jeon, Qiang Fu, Daelynn R. Buelow, Marissa Pioso, Shuiying Hu, Hiroto Inaba, Raul C. Ribeiro, Jeffrey E. Rubnitz, Tanja A. Gruber, R. Kiplin Guy, Sharyn D. Baker

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Improvement in survival has been achieved for children and adolescents with AML but is largely attributed to enhanced supportive care as opposed to the development of better treatment regimens. High risk subtypes continue to have poor outcomes with event free survival rates <40% despite the use of high intensity chemotherapy in combination with hematopoietic stem cell transplant. Here we combine high-throughput screening, intracellular accumulation assays, and in vivo efficacy studies to identify therapeutic strategies for pediatric AML. We report therapeutics not currently used to treat AML, gemcitabine and cabazitaxel, have broad anti-leukemic activity across subtypes and are more effective relative to the AML standard of care, cytarabine, both in vitro and in vivo. JAK inhibitors are selective for acute megakaryoblastic leukemia and significantly prolong survival in multiple preclinical models. Our approach provides advances in the development of treatment strategies for pediatric AML.

Original language	English
Article number	2189
Journal	Nature Communications
Volume	10
Issue number	1
DOIs	https://doi.org/10.1038/s41467-019-09917-0
State	Published - Dec 1 2019

Bibliographical note

Funding Information:
The authors thank Drs. Alex Sparreboom and Navjot Pabla for helpful discussions and insights and Dr. Adrianne M. Dorrance for providing critical reagents. This work was supported by the American Lebanese Syrian Associated Charities (ALSAC) of St. Jude Children’s Research Hospital, OSU Comprehensive Cancer Center Pelotonia Funds, National Institutes of Health Cancer Center Support Grant P30 CA021765 (SJCRH), P30 CA016058 (OSUCCC), R01 CA138744 (S.D.B.), and F32 CA180513 (C.D.D.).

Publisher Copyright:
© 2019, The Author(s).

ASJC Scopus subject areas

Chemistry (all)
Biochemistry, Genetics and Molecular Biology (all)
General
Physics and Astronomy (all)

Access to Document

10.1038/s41467-019-09917-0

Cite this

Drenberg, C. D., Shelat, A., Dang, J., Cotton, A., Orwick, S. J., Li, M., Jeon, J. Y., Fu, Q., Buelow, D. R., Pioso, M., Hu, S., Inaba, H., Ribeiro, R. C., Rubnitz, J. E., Gruber, T. A., Guy, R. K., & Baker, S. D. (2019). A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications, 10(1), Article 2189. https://doi.org/10.1038/s41467-019-09917-0

@article{ddbe8835a0694121be1756da1efb6d5a,

title = "A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML",

abstract = "Improvement in survival has been achieved for children and adolescents with AML but is largely attributed to enhanced supportive care as opposed to the development of better treatment regimens. High risk subtypes continue to have poor outcomes with event free survival rates <40% despite the use of high intensity chemotherapy in combination with hematopoietic stem cell transplant. Here we combine high-throughput screening, intracellular accumulation assays, and in vivo efficacy studies to identify therapeutic strategies for pediatric AML. We report therapeutics not currently used to treat AML, gemcitabine and cabazitaxel, have broad anti-leukemic activity across subtypes and are more effective relative to the AML standard of care, cytarabine, both in vitro and in vivo. JAK inhibitors are selective for acute megakaryoblastic leukemia and significantly prolong survival in multiple preclinical models. Our approach provides advances in the development of treatment strategies for pediatric AML.",

author = "Drenberg, {Christina D.} and Anang Shelat and Jinjun Dang and Anitria Cotton and Orwick, {Shelley J.} and Mengyu Li and Jeon, {Jae Yoon} and Qiang Fu and Buelow, {Daelynn R.} and Marissa Pioso and Shuiying Hu and Hiroto Inaba and Ribeiro, {Raul C.} and Rubnitz, {Jeffrey E.} and Gruber, {Tanja A.} and Guy, {R. Kiplin} and Baker, {Sharyn D.}",

note = "Funding Information: The authors thank Drs. Alex Sparreboom and Navjot Pabla for helpful discussions and insights and Dr. Adrianne M. Dorrance for providing critical reagents. This work was supported by the American Lebanese Syrian Associated Charities (ALSAC) of St. Jude Children{\textquoteright}s Research Hospital, OSU Comprehensive Cancer Center Pelotonia Funds, National Institutes of Health Cancer Center Support Grant P30 CA021765 (SJCRH), P30 CA016058 (OSUCCC), R01 CA138744 (S.D.B.), and F32 CA180513 (C.D.D.). Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = dec,

day = "1",

doi = "10.1038/s41467-019-09917-0",

language = "English",

volume = "10",

number = "1",

}

Drenberg, CD, Shelat, A, Dang, J, Cotton, A, Orwick, SJ, Li, M, Jeon, JY, Fu, Q, Buelow, DR, Pioso, M, Hu, S, Inaba, H, Ribeiro, RC, Rubnitz, JE, Gruber, TA, Guy, RK & Baker, SD 2019, 'A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML', Nature Communications, vol. 10, no. 1, 2189. https://doi.org/10.1038/s41467-019-09917-0

TY - JOUR

T1 - A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

AU - Drenberg, Christina D.

AU - Shelat, Anang

AU - Dang, Jinjun

AU - Cotton, Anitria

AU - Orwick, Shelley J.

AU - Li, Mengyu

AU - Jeon, Jae Yoon

AU - Fu, Qiang

AU - Buelow, Daelynn R.

AU - Pioso, Marissa

AU - Hu, Shuiying

AU - Inaba, Hiroto

AU - Ribeiro, Raul C.

AU - Rubnitz, Jeffrey E.

AU - Gruber, Tanja A.

AU - Guy, R. Kiplin

AU - Baker, Sharyn D.

N1 - Funding Information: The authors thank Drs. Alex Sparreboom and Navjot Pabla for helpful discussions and insights and Dr. Adrianne M. Dorrance for providing critical reagents. This work was supported by the American Lebanese Syrian Associated Charities (ALSAC) of St. Jude Children’s Research Hospital, OSU Comprehensive Cancer Center Pelotonia Funds, National Institutes of Health Cancer Center Support Grant P30 CA021765 (SJCRH), P30 CA016058 (OSUCCC), R01 CA138744 (S.D.B.), and F32 CA180513 (C.D.D.). Publisher Copyright: © 2019, The Author(s).

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Improvement in survival has been achieved for children and adolescents with AML but is largely attributed to enhanced supportive care as opposed to the development of better treatment regimens. High risk subtypes continue to have poor outcomes with event free survival rates <40% despite the use of high intensity chemotherapy in combination with hematopoietic stem cell transplant. Here we combine high-throughput screening, intracellular accumulation assays, and in vivo efficacy studies to identify therapeutic strategies for pediatric AML. We report therapeutics not currently used to treat AML, gemcitabine and cabazitaxel, have broad anti-leukemic activity across subtypes and are more effective relative to the AML standard of care, cytarabine, both in vitro and in vivo. JAK inhibitors are selective for acute megakaryoblastic leukemia and significantly prolong survival in multiple preclinical models. Our approach provides advances in the development of treatment strategies for pediatric AML.

AB - Improvement in survival has been achieved for children and adolescents with AML but is largely attributed to enhanced supportive care as opposed to the development of better treatment regimens. High risk subtypes continue to have poor outcomes with event free survival rates <40% despite the use of high intensity chemotherapy in combination with hematopoietic stem cell transplant. Here we combine high-throughput screening, intracellular accumulation assays, and in vivo efficacy studies to identify therapeutic strategies for pediatric AML. We report therapeutics not currently used to treat AML, gemcitabine and cabazitaxel, have broad anti-leukemic activity across subtypes and are more effective relative to the AML standard of care, cytarabine, both in vitro and in vivo. JAK inhibitors are selective for acute megakaryoblastic leukemia and significantly prolong survival in multiple preclinical models. Our approach provides advances in the development of treatment strategies for pediatric AML.

UR - http://www.scopus.com/inward/record.url?scp=85065791066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065791066&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-09917-0

DO - 10.1038/s41467-019-09917-0

M3 - Article

C2 - 31097698

AN - SCOPUS:85065791066

SN - 2041-1723

VL - 10

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 2189

ER -

A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this